Table 1.
Demographics and clinical characteristics of liver transplant recipients overall and by donor types
| Variable | Missing | Total (n=2,563) | LDLT (n=1,956) | DDLT (n=607) |
|---|---|---|---|---|
| Age (years) | 0 | 53.9±8.9 | 54.3±8.4 | 52.6±10.3 |
| Sex, male | 0 | 1,850 (72.2) | 1,441 (73.7) | 409 (67.4) |
| BMI ≥25 kg/m2 | 2 | 937 (36.6) | 725 (37.1) | 212 (34.9) |
| Underlying liver disease | 0 | |||
| Hepatitis B | 1,433 (55.9) | 1,184 (60.5) | 249 (41.0) | |
| Alcoholic | 622 (24.3) | 401 (20.5) | 221 (36.4) | |
| Hepatitis C | 179 (7.0) | 133 (6.8) | 46 (7.6) | |
| Cryptogenic | 138 (5.4) | 111 (5.7) | 27 (4.4) | |
| Others | 191 (7.5) | 127 (6.5) | 64 (10.5) | |
| Acute hepatitis | 0 | 109 (4.3) | 52 (2.7) | 57 (9.4) |
| Liver cancer | 1,262 (49.2) | |||
| HCC | 0 | 1,229 (48.0) | 1,056 (54.0) | 173 (28.5) |
| CCC | 11 (0.4) | – | – | |
| Combined HCC+CCC | 20 (0.8) | – | – | |
| Other malignancy | 2 (0.1) | – | – | |
| Pretransplant HCC status | 3 | |||
| Within Milan criteria | 790 (30.8) | 677 (34.6) | 113 (18.6) | |
| Beyond Milan criteria | 212 (8.3) | 176 (9.0) | 36 (5.9) | |
| No viable tumor | 224 (8.7) | 201 (10.3) | 23 (3.8) | |
| Incidental liver cancer | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Hypertension | 0 | 454 (17.7) | 363 (18.6) | 91 (15.0) |
| Diabetes mellitus | 0 | 629 (24.5) | 480 (24.5) | 149 (24.5) |
| MELD score (n=2,562) | 1 | |||
| <15 | 1,319 (51.5) | 1,234 (63.1) | 85 (14.0) | |
| 15–34 | 996 (38.9) | 662 (33.9) | 334 (55.0) | |
| ≥35 | 247 (9.6) | 59 (3.0) | 188 (31.0) | |
| CTP classification | ||||
| A (≤6) | 0 | 742 (29.0) | 723 (37.0) | 19 (3.1) |
| B (7–9) | 860 (33.6) | 769 (39.3) | 91 (15.0) | |
| C (≥10) | 961 (37.5) | 464 (23.7) | 497 (81.9) | |
| KONOS status | ||||
| Score 1 | 0 | 58 (2.2) | 9 (0.5) | 49 (8.1) |
| Score 2 | 163 (6.4) | 35 (1.8) | 128 (21.1) | |
| Score 3 | 150 (5.9) | 58 (3.0) | 92 (15.2) | |
| Score 4 | 416 (16.2) | 262 (13.4) | 154 (25.4) | |
| Score 5 | 1,776 (69.3) | 1,592 (81.4) | 184 (30.3) | |
| ABO incompatible | 0 | 408 (15.9) | 404 (20.7) | 4 (0.7) |
| Graft type | 0 | |||
| Whole liver | 577 (22.5) | 0 (0.0) | 577 (95.1) | |
| Right liver graft | 87 (3.4) | 85 (4.3) | 2 (0.3) | |
| Left liver graft | 1,899 (74.1) | 1,871 (95.7) | 28 (4.6) | |
| Graft-recipient weight ratio for LDLT < 0.8 | 33 | – | 159 (8.3) | – |
| Type of donor operation in LDLT (n=1,956) | 0 | |||
| Minimal invasive surgery | – | 388 (19.8) | – | |
| Conventional, open | – | 1,568 (80.2) | – | |
| Use of steroids | 2,288 (89.3) | 1,767 (90.3) | 521 (85.8) | |
| Use of anti-metabolites | 1,892 (73.8) | 1,485 (75.9) | 407 (67.1) | |
| Use of mTOR inhibitors | 282 (11.0) | 212 (10.8) | 70 (11.5) |
Values are presented as mean±standard deviation or number (%).
LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; BMI, body mass index; HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma; MELD, Model for End-Stage Liver Disease; CTP, Child-Turocotte-Pugh; KONOS, Korean Network for Organ Sharing; mTOR, mammalian target of rapamycin.